| The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes D Altshuler, JN Hirschhorn, M Klannemark, CM Lindgren, MC Vohl, ... Nature genetics 26 (1), 76, 2000 | 2091 | 2000 |
| Simvastatin with or without ezetimibe in familial hypercholesterolemia JJP Kastelein, F Akdim, ESG Stroes, AH Zwinderman, ML Bots, ... New England Journal of Medicine 358 (14), 1431-1443, 2008 | 1539 | 2008 |
| Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? I Lemieux, A Pascot, C Couillard, B Lamarche, A Tchernof, N Alméras, ... Circulation 102 (2), 179-184, 2000 | 1149 | 2000 |
| Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease JD Rioux, MJ Daly, MS Silverberg, K Lindblad, H Steinhart, Z Cohen, ... Nature genetics 29 (2), 223, 2001 | 894 | 2001 |
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised … FJ Raal, RD Santos, DJ Blom, AD Marais, MJ Charng, WC Cromwell, ... The Lancet 375 (9719), 998-1006, 2010 | 778 | 2010 |
| Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on … EA Stein, D Gipe, J Bergeron, D Gaudet, R Weiss, R Dufour, R Wu, ... The Lancet 380 (9836), 29-36, 2012 | 583 | 2012 |
| PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial FJ Raal, EA Stein, R Dufour, T Turner, F Civeira, L Burgess, G Langslet, ... The Lancet 385 (9965), 331-340, 2015 | 571 | 2015 |
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study M Cuchel, EA Meagher, H du Toit Theron, DJ Blom, AD Marais, ... the Lancet 381 (9860), 40-46, 2013 | 549 | 2013 |
| Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia C Gagné, D Gaudet, E Bruckert Circulation 105 (21), 2469-2475, 2002 | 499 | 2002 |
| Common variants in the NLRP3 region contribute to Crohn's disease susceptibility AC Villani, M Lemire, G Fortin, E Louis, MS Silverberg, C Collette, N Baba, ... Nature genetics 41 (1), 71, 2009 | 425 | 2009 |
| Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region JC Florez, N Burtt, PIW De Bakker, P Almgren, T Tuomi, J Holmkvist, ... Diabetes 53 (5), 1360-1368, 2004 | 323 | 2004 |
| Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia D Gaudet, VJ Alexander, BF Baker, D Brisson, K Tremblay, W Singleton, ... New England Journal of Medicine 373 (5), 438-447, 2015 | 298 | 2015 |
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial D Gaudet, J Méthot, S Déry, D Brisson, C Essiembre, G Tremblay, ... Gene therapy 20 (4), 361, 2013 | 292 | 2013 |
| Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess … EA Stein, R Dufour, C Gagne, D Gaudet, C East, JM Donovan, W Chin, ... Circulation 126 (19), 2283-2292, 2012 | 274 | 2012 |
| Targeting APOC3 in the familial chylomicronemia syndrome D Gaudet, D Brisson, K Tremblay, VJ Alexander, W Singleton, SG Hughes, ... New England Journal of Medicine 371 (23), 2200-2206, 2014 | 261 | 2014 |
| Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes W Winckler, MN Weedon, RR Graham, SA McCarroll, S Purcell, ... Diabetes 56 (3), 685-693, 2007 | 228 | 2007 |
| Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperapobetalipoproteinemia MC Vohl, P Lepage, D Gaudet, CG Brewer, C Bétard, P Perron, G Houde, ... Journal of Lipid Research 41 (6), 945-952, 2000 | 226 | 2000 |
| 5′ flanking variants of resistin are associated with obesity JC Engert, MC Vohl, SM Williams, P Lepage, JC Loredo-Osti, J Faith, ... Diabetes 51 (5), 1629-1634, 2002 | 218 | 2002 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino Sr, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 213 | 2018 |
| Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial H Bays, D Gaudet, R Weiss, JL Ruiz, GF Watts, I Gouni-Berthold, ... The Journal of Clinical Endocrinology & Metabolism 100 (8), 3140-3148, 2015 | 204 | 2015 |
